| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911109 | Lung Cancer | 2014 | 5 Pages |
Abstract
Our results suggest that erlotinib represents a valid treatment option for patients with KRAS WT lung adenocarcinoma and, moreover, that KRAS mutation analysis could help to identify clinically relevant subgroups of NSCLC patients that may benefit from EGFR-TKI therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Veronika Sarosi, Gyorgy Losonczy, Eva Francovszky, Edina Tolnay, Szilvia Torok, Gabriella Galffy, Balazs Hegedus, Balazs Dome, Gyula Ostoros,